Key Takeaways
- • Thrive Therapies, a tech-enabled pediatric healthcare company based in Dallas, Texas, announced $7.7 million in funding.
- • The round was led by LiveOak Ventures, with participation from Activate Venture Partners and the Charter School Growth Fund.
- • Thrive delivers therapy, evaluations and behavioral health care to students with disabilities in more than 200 schools and districts across six states.
- • Proceeds will fund expansion into new markets, growth of clinical teams, and advancement of Thrive Clinical, its clinical intelligence platform.
Summary
Thrive Therapies, a tech-enabled pediatric healthcare company headquartered in Dallas, Texas, has announced $7.7 million in funding. The round was led by LiveOak Ventures, with participation from Activate Venture Partners and the Charter School Growth Fund, according to the company's announcement.
The company delivers therapy, evaluations and behavioral health care to children with disabilities inside schools. It currently serves more than 200 schools and districts across six states: Florida, North Carolina, Ohio, Tennessee, Texas and Washington. Its model combines clinical excellence, data intelligence, Medicaid revenue cycle management and outcomes reporting.
Thrive said it will use the capital to enter new markets, expand its clinical teams, and advance Thrive Clinical, its proprietary clinical intelligence platform. The disclosure did not specify the valuation, the round's security type, or the company's revenue or growth metrics.
FinSMEs also reported the $7.7 million raise under the headline "Thrive Therapies Raises $7.7M in Funding."
The company delivers therapy, evaluations and behavioral health care to children with disabilities inside schools. It currently serves more than 200 schools and districts across six states: Florida, North Carolina, Ohio, Tennessee, Texas and Washington. Its model combines clinical excellence, data intelligence, Medicaid revenue cycle management and outcomes reporting.
Thrive said it will use the capital to enter new markets, expand its clinical teams, and advance Thrive Clinical, its proprietary clinical intelligence platform. The disclosure did not specify the valuation, the round's security type, or the company's revenue or growth metrics.
FinSMEs also reported the $7.7 million raise under the headline "Thrive Therapies Raises $7.7M in Funding."
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.